Achim has published widely in social science journals, biomedical and scientific journals as well as online platforms. He has also edited a special issue in Science as Culture, initiated and co-edited a double special issue in Regenerative Medicine, published an edited book volume with Springer, and co-created an educational digital resource (with colleagues from the ERC-funded EuroStemCell platform in Edinburgh). A monograph with McGill-Queens University Press is under contract. He serves as an associate editor for the journal Science as Culture.
1. Special Issues and Edited Book Volume
Rosemann, A., Atkinson, S. and S. Molyneux-Hodgson (under contract). Making Responsible Futures: Industrial Biotechnology and the Challenges of Innovation. Quebec and London: McGill-Queens University Press.
Rosemann, A. (2019) ‘Alter-standardizing Clinical Trials: Implications for Policy and Practice’, Special Issue, Science as Culture, 28(2), 122 – 263.
Rosemann, A., Barfoot, J., and C. Blackburn (2017) 'Regenerative Medicine in Society: Interdisciplinary Perspectives (Part 1)', Regenerative Medicine, 12(6), 577-731 [September issue 2017].
Barfoot, J., Rosemann, A., and C. Blackburn (2017) 'Regenerative Medicine in Society: Interdisciplinary Perspectives (Part 2)', Regenerative Medicine, 12(7), 733-892 [October issue 2017]
Pham, P.V., and A. Rosemann (2017) Stem Cells in Clinical Applications (Volume 6): Safety, Ethics and Regulation. Heidelberg and New York: Springer Nature (Series Editor: Phuc Van Pham). ISBN 978-3-319-591643.
2. Refereed Articles, Book Chapters, Reports
Bernd Carsten Stahl, Simisola Akintoye, Lise Bitsch, Berit Bringedal, Damian Eke, Michele Farisco, Karin Grasenick, Manuel Guerrero, William Knight, Tonii Leach, Sven Nyholm, George Ogoh, Achim Rosemann, Arleen Salles, Julia Trattnig & Inga Ulnicane (2021) From Responsible Research and Innovation to responsibility by design, Journal of Responsible Innovation, DOI: 10.1080/23299460.2021.1955613
Aicardi, C., Bitsch, L., Datta Burton, S., Evers, K., Farisco, M., Mahfoud, T., Rose, N., Rosemann, A., Salles, A., Stahl, B. C. & I. Ulnicane (2021) Opinion on Trust and Transparency in Artificial Intelligence, Ethics and Society, the Human Brain Project; Report. 36 p., DOI: https://doi.org/10.5281/zenodo.4588647
Rosemann, A., Kgwadi, B., Zwart, H., Adams, A., Agu, C., Archibong, U., Dalton, G., De Castro, F., Eshareturi, C., Kaul, N., Novella Abril, I., Sanches De Madariaga, I., Utam, U. K., Wakunuma, K., & A. Tash (2021). Mapping the UNESCO Recommendations on Science and Scientific Researchers to the UN Sustainable Development Goals. Research output: Report. https://doi.org/10.5281/zenodo.5387396
Rosemann, A., and K. Wakunuma (2021) Responsible Research and Innvoation Networked Globally: Focus Analysis of the Role of Industry Innovators. Research output: Report. 50 p. https://doi.org/10.5281/zenodo.5025433
Rosemann, A. and S. Molyneux-Hodgson (2020) Industrial Biotechnology: To what extent is Responsible Innovation on the Agenda?, Trends in Biotechnology, Doi: 10.1016j.tibtech.2019.07.006
Rosemann, A., Balen, A., Nerlich, B., Hauskeller, C., Sleeboom-Faulkner, M., Hartley, S., X.Q. Zhang and N. Lee (2019) Heritable human gene editing in global perspective: national and international policy challenges. Hastings Centre Report, 49(3), 31-42.
Rosemann, A. (2019). Alter-standardizing clinical trials: The gold standard in the cross-fire, Science as Culture, 28(2), 125-146.
Bortz, G., Rosemann, A., and F. Vasen (2019). Shaping Stem Cell Therapies in Argentina: Regulation, Risk Management and Innovation Policies, Sociologias, 21(50), 116-155.
Rosemann, A. (2019) Balancing social justice and risk management in the governance of gene drive technology: lessons from stem cell research. In: Hauskeller, C., Manzeschke, A., and A. Pichl (Eds). The Matrix of Stem Cell Research Revisited. London and New York: Routledge.
Rosemann, A., Vasen, F. and G. Bortz (2018). Global Diversification in Medicine Regulation: Insights from Regenerative Stem Cell Medicine, Science as Culture, 38(2), 223-249.
Rosemann, A. and H.Y. Luo (2018) Attitudes on the Donation of Human Embryos for Stem Cell Research among Chinese IVF Patients and Students. Journal of Bioethical Inquiry. Doi.org/10.1007/s11673-018-9862-9.
Rosemann, A., Bortz, G., and F. Vasen (2018). Regulatory developments for non-hematopoietic stem cell therapeutics: perspectives from the EU, the USA, Japan, China, India, Argentina and Brazil. In: X.D. Chen (ed.) A Roadmap to non-Hematopoietic Stem Cell-based Therapeutics: From the Bench to the Clinic. New York: Elsevier Academic Press.
Jiang, L. and A. Rosemann (2018) Human embryo gene editing in China: the uncertain legal status of the embryo, Biosocieties. Doi.org/10.1057/s41292-018-0116-1
Sleeboom-Faulkner, M., Chen, H.D. and Rosemann, A. (2018) Regulatory capacity building and the governance of clinical stem cell research in China, Science and Public Policy. Doi/10.1093/scipol/scx077/4675127)
Rosemann, A., Jiang, L. and X.Q. Zhang (2018). The Regulatory and Legal Situation of Human Embryo, Gamete and Germ Line Gene Editing Research and Clinical Applications in the People’s Republic of China. Background Paper. Nuffield Council on Bioethics (http://nuffieldbioethics.org/wp-content/uploads/Background-paper-GEHR.pdf)
Rosemann, A., Barfoot, J. and C. Blackburn (2017) Special Focus Issue on Regenerative Medicine in Society: Interdisciplinary Perspectives (Part I) – Foreword. Regenerative Medicine, 12(6), 577-580. (September Issue 2017).
Barfoot, J., A. Rosemann and C. Blackburn (2017) Special Focus Issue on Regenerative Medicine in Society: Interdisciplinary Perspectives (Part II) – Foreword. Regenerative Medicine, 12(7), 733-736. (October Issue 2017).
Bortz, G., Vasen, F. and A. Rosemann (2017) Entre oportunidad y riesgo. Regulación, expectativas y políticas CTI para células madre en Argentina. Ciencia, Docencia y Tecnología, 54, 38-74.
Rosemann, A., L. Jiang and X.Q. Zhang (2017) Human Germ Line Gene Editing: Why comparative, cross-national studies on public viewpoints are important. Anthropology, DOI: 10.4172/2332-0915.1000175
Pham, P.V., and A. Rosemann (2017) Safety, Ethics and Regulation - Preface. In: Pham, P.V. and A. Rosemann (eds.) Stem Cells in Clinical Applications: Safety, Ethics and Regulations. Heidelberg and New York: Springer
Rosemann, A., Zhang Z.Q., Sui, S.L., Ely, A., and Sleeboom-Faulkner, M. (2017) The regulatory situation for clinical stem cell research in China. In: Pham, P.V. and A. Rosemann (eds.) Stem Cells in Clinical Applications: Safety, Ethics and Regulations. Heidelberg and New York: Springer, 275-290.
Rosemann, A. (2017) Contested Tissues: the donation of oocytes and embryos in the IVF-Stem Cell Interface in China. In: Pham, P.V. and A. Rosemann (eds.) Stem Cells in Clinical Applications: Safety, Ethics and Regulations. Heidelberg and New York: Springer, 291-300.
Rosemann, A. (2017) Challenges to international stem cell clinical trials in countries with divergent regulations. In: Pham, P.V. and A. Rosemann (eds.) Stem Cells in Clinical Applications: Safety, Ethics and Regulations. Heidelberg and New York: Springer, 301-319.
Rosemann, A. and N. Chaisinthop (2016) The pluralization of the international: networks of resistance and alter-standardization in regenerative stem cell medicine. Social Studies of Science, 46(1), 112-39.
Rosemann, A., Bortz, G., Vasen, F., and M. Sleeboom-Faulkner (2016) Global regulatory developments for clinical stem cell research: diversification and challenges to collaborations, Regenerative Medicine, 11(7), 647-657.
Sleeboom-Faulkner, M. Chekar, C. Faulkner, A. Heitmeyer, C., Marouda, M. Rosemann, A, et al. (2016) National Home-Keeping and the Regulation of Translational Stem Cell Applications: An international perspective, Social Science & Medicine, 153, 240-249
Rosemann, A. and M. Sleeboom-Faulkner (2016) New regulation for clinical stem cell research in China – expected impact and challenges for implementation, Regenerative Medicine, Doi:10.2217/rme.15.80
Rosemann, A. (2015) Stem cell treatments for neurodegenerative diseases: challenges from a science, business and healthcare perspective, Neurodegenerative Disease Management, 5(2), 85-87.
Rosemann, A. (2015) Multi-country Stem Cell Trials: the Need for an International Support Structure, Stem Cell Research, 14(3), 396-400.
Rosemann, A. (2014) Standardization as situation-specific achievement: Regulatory diversity and the production of value in intercontinental collaborations in stem cell medicine, Social Science & Medicine, 122, 72-80.
Rosemann, A. (2014) 'Modalities of value, exchange, solidarity: the social life of stem cells in China', in: M. Sleeboom-Faulkner (Ed.) Stem Cell Research in Asia: Looking beyond regulatory exteriors. London/New York: Routledge.
Rosemann, A. (2014) Why regenerative stem cell medicine progresses slower than expected, Journal of Cellular Biochemistry, 15(12), 2073-2076.
Rosemann, A. (2013) Scientific Multipolarization: Its impact on international clinical research collaborations and theoretical implications, Science Technology and Society, 18(3), 339-359.
Rosemann, A. (2013) Medical Innovation and National Experimental Pluralism: Insights from Clinical Stem Cell Research and Applications in China, BioSocieties, 8(1), 58-74.
Rosemann, A. (2011) Modalities of Value, Exchange, Solidarity: Exploring the Social Life of Stem Cells in China, New Genetics and Society, 30(2), 181-192.
Rosemann, A. (2010) 'The IVF-Stem Cell Interface in China: Ontologies, Value-perceptions and Donation-practices of Embryonic Forms of Life ', in O. Doering (ed.), Life Sciences in Translation - A Sino-European Dialogue on Ethical Governance of the Life Sciences, BIONET, Online Textbook, Brussels: European Commission, 168-179.
Rosemann, A. (2009) `Life without Value? Listening to the voices of embryo donors for human embryonic stem cell research in China', The Newsletter, International Institute of Asian Studies, No 52, winter 2009, 15-6. (URL: http://sro.sussex.ac.uk/53217/).
3. Digital and Online Publications
Rosemann, A., and S. Molyneux-Hodgson (2020). The National Industrial Biotechnology to 2030: What is the role for responsible research and innovation? The Biochemist Blog. Weblink: Part 1 and Part 2.
Nerlich, B. and A. Rosemann (2019) Towards a global dialogue about heritable germline editing: Mapping needs and challenges. BioMed Central – On Society Blog (July 23, 2019). Weblink: https://blogs.biomedcentral.com/on-society/2019/07/23/towards-a-global-dialogue-about-heritable-germline-editing-mapping-needs-and-challenges/
Rosemann, A. and B. Nerlich (2019). Heritable Germline Editing: National and International Governance Challenges and Policy Options. Making Science Public Blog (July 27, 2019). Weblink: https://blogs.nottingham.ac.uk/makingsciencepublic/2019/07/27/heritable-genome-editing-national-and-international-governance-challenges-and-policy-options/
Rosemann, A., Barfoot, J., Price-Evans, A. and C. Blackburn (2017). Regenerative Medicine in Society – Introduction to the Digital Gateway. Weblink: https://www.eurostemcell.org/regenerative-medicine-society.
Rosemann, A. (2017) The Regulation of Clinical Stem Cell Research and Applications: three dynamics of global regulatory diversification (in three parts). Regenerative Medicine Network (RegMedNet). Spotlight to Cell Therapy Regulation (June 30, 2017). Weblink: Part 1, Part 2, Part 3.
Rosemann, A. (2013) ‘Stem Cell Clinical Trials’, Centre for Bionetworking, Educational Resource (URL: http://sro.sussex.ac.uk/53219/)
4. Educational Resources:
University of Warwick (2018). Human Germline Gene Editing in Global Context. Project Website (Weblink: https://warwick.ac.uk/fac/soc/ces/research/current/humangermlinegene)
EuroStemCell (2017). A Digital Gateway: Regenerative Medicine in Society. EuroStemCell Website; Co-production with Jan Barfoot, Adam Price-Evans, Ryan Lewis, Anna Couturier, and Clare Blackburn of the University of Edinburgh. (Weblink: https://www.eurostemcell.org/regenerative-medicine-society).
Explanatory Note: This Digital Gateway comprises 27 short contributions of leading inter-disciplinary scholars written for patients, practitioners, and the wider public.
5. Research briefings, science policy & consultancy reports
Rosemann, A. (2017) Germ Line Gene Editing in Global Context: Challenges and Needs from a UK Perspective; report for the Nuffield Council of Bioethics's Working Party: “Genome Editing in Human Reproduction.”
Rosemann, A. (2015) ’Clinical stem cell research collaborations between China and the USA: opportunities, challenges, possible solutions’, client: Don Reed, Palo Alto, CA, USA (Californians for Cure; Sponsor of Roman Reed Spinal Cord Injury Research Act; CA)
Rosemann, A., Zhang XQ., Sui SS., Su YY, and A. Ely (2013) 'Country Report: Stem Cell Research in China'; working paper series, Centre for Bionetworking, University of Sussex.
Rosemann, A. (2011) `Contextualizing Experimental Stem Cell Applications in China'; Report: Department of Regulatory Affairs, Western Institutional Review Board, Olympia, USA.
Rosemann, A. (2011) ‘Ethical Strategies in Stem Cell Banking: UK and Taiwan in cross-national Perspective', Report: submitted to: Taiwan Stem Cell Bank, Hsinchu, Taiwan.